Offering HPV vaccine

PreclinicalVaccine

UUniversity Medical Centre Ljubljana

Offering HPV vaccine is one of 37 biologic programs targeting Papilloma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PapillomaActive, not recruiting

PapillomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Papilloma

#DrugCompanyPhaseTrials

Cervarix

GSK

Phase 3

9 2

GSK 257049

GSK

Phase 3

6 3

Comparator: Pbo

Merck & Co.

Phase 3

3 4

Gardasil

Merck & Co.

Phase 3

11 5

Engerix-B

GSK

Phase 3

1 6

Havrix

GSK

Phase 3

1 7

Fludara

Sanofi

Phase 2

2 8

Opdivo

Bristol-Myers Squibb

Phase 2

1 9

Libtayo

Regeneron

Phase 2

1 10

Boostrix

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Papilloma1 trial

Characteristics of Human Papillomavirus (HPV) Infections and HPV Vaccine Attitudes Among Slovenian Women After the Introduction of HPV Vaccination

Recruiting·UUniversity Medical Centre Ljubljana·N/A·NCT06995157·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Offering HPV vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Offering HPV vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Offering HPV vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Medical Centre Ljubljana company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Preclinical[1]
Company: UUniversity Medical Centre Ljubljana

Offering HPV vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Papilloma1 trial

References

Drug Info

Quick Facts

Related News